We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 2

1.
Fig. 1

Fig. 1. From: A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.

Effect of 17-AAG dose on docetaxel clearance (n = 33). Docetaxel pharmacokinetic data were not collected from patients receiving 80 mg/m2 17-AAG

Gopa Iyer, et al. Cancer Chemother Pharmacol. 2012 April;69(4):1089-1097.
2.
Fig. 2

Fig. 2. From: A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.

Immunoblot studies of peripheral blood mononuclear cells collected pretreatment and days 2, 3, 8, and 15 of cycle 1. The four representative patients shown were all treated at the docetaxel 75 mg/m2 and 17-AAG 450 mg/m2 dose level

Gopa Iyer, et al. Cancer Chemother Pharmacol. 2012 April;69(4):1089-1097.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk